Share price · HCM
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when HCM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Sep 2026+17.2%
- 30 Jul 2026-5.4%
- 20 Jul 2026+4.4%
Nothing announced by HCM that day or the session before.
- 17 Jul 2026-6.6%
Nothing announced by HCM that day or the session before.
- 7 Jul 2026-4.9%
Nothing announced by HCM that day or the session before.
- 17 Jun 2026-3.5%
Nothing announced by HCM that day or the session before.
- 28 May 2026-4.2%
Nothing announced by HCM that day or the session before.
- 21 Apr 2026-5.0%
Nothing announced by HCM that day or the session before.
- 11 Mar 2026+4.9%
- 2 Feb 2026-2.9%
Nothing announced by HCM that day or the session before.
Share of unusual movement by asset
For each asset, the share of HCM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Fruquintinib(Fruzaqla / Elunate) | Approved | VEGFR1/2/3Small molecule | Colorectal CancerRenal Cell CarcinomaEndometrial Cancer Metastatic Colorectal Cancer, Advanced Metastatic Colorectal Cancer |
Savolitinib(Orpathys) | Phase 3 | METSmall molecule | Non-Small Cell Lung CancerRenal Cell Carcinoma |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(26)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
The 12 most recent of 26 past events are shown.
Financial reports
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $549M | $148M | $71M+ $1.3B short-term inv. | —-$65M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $630M | $212M | $154M+ $682M short-term inv. | —$0.5M operating cash flow | report ↗ |
| 2023-FY | $838M | $302M | $284M+ $603M short-term inv. | —$219M operating cash flow | report ↗ |
| 2022-FY | $426M | $387M | $313M+ $318M short-term inv. | $90M-$269M operating cash flow | report ↗ |
| 2021-FY | $356M | $299M | $378M+ $634M short-term inv. | $49M-$204M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-20 | Chiu Lorenso · Deputy Chief Financial Officer | Other (see filing) (derivative) | 5,176 | — | — | Form 4 |
| 2026-05-20 | Su Wei-guo · director, CEO and CSO | Other (see filing) (derivative) | 132,864 | — | — | Form 4 |
| 2026-05-20 | Nixon Charles George Rupert · Group General Counsel | Other (see filing) (derivative) | 7,445 | — | — | Form 4 |
| 2026-05-20 | Cheng Chig Fung · director, Acting CEO and CFO | Other (see filing) (derivative) | 30,157 | — | — | Form 4 |
| 2026-05-20 | Chiu Lorenso · Deputy Chief Financial Officer | Other (see filing) (derivative) | 8,863 | — | — | Form 4 |
| 2026-05-20 | Su Wei-guo · director, CEO and CSO | Other (see filing) (derivative) | 75,140 | — | — | Form 4 |
| 2026-05-20 | Nixon Charles George Rupert · Group General Counsel | Other (see filing) (derivative) | 7,644 | — | — | Form 4 |
| 2026-05-20 | Cheng Chig Fung · director, Acting CEO and CFO | Other (see filing) (derivative) | 26,307 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 53 reporting institutions held 4.3M shares ($63.6M, 2.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | SCHRODER INVESTMENT MANAGEMENT GROUP | 1,477,494 | $22.1M |
| 2 | Allianz Asset Management GmbH | 837,475 | $12.5M |
| 3 | STATE STREET CORP | 304,829 | $4.6M |
| 4 | AIA Group Ltd | 291,229 | $4.4M |
| 5 | M&G PLC | 255,468 | $3.8M |
| 6 | Amundi | 232,246 | $3.5M |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 132,062 | $2.0M |
| 8 | BNP PARIBAS FINANCIAL MARKETS | 106,504 | $1.6M |
| 9 | Crossmark Global Holdings, Inc. | 84,963 | $1.3M |
| 10 | JANE STREET GROUP, LLC | 76,514 | $1.1M |
| 11 | Tidal Investments LLC | 67,385 | $1.0M |
| 12 | DIMENSIONAL FUND ADVISORS LP | 55,969 | $837K |
| 13 | XY Capital Ltd | 48,394 | $724K |
| 14 | UBS Group AG | 44,758 | $670K |
| 15 | CITADEL ADVISORS LLC | 30,514 | $456K |